Search

Your search keyword '"Stephanie E Combs"' showing total 118 results
Start Over Author "Stephanie E Combs" Journal radiotherapy and oncology
118 results on '"Stephanie E Combs"'

1. Biomarker signatures for primary radiochemotherapy of locally advanced HNSCC – Hypothesis generation on a multicentre cohort of the DKTK-ROG

Author

Steffen Löck, Annett Linge, Fabian Lohaus, Nadja Ebert, Volker Gudziol, Alexander Nowak, Ingeborg Tinhofer, Goda Kalinauskaite, Maja Guberina, Martin Stuschke, Panagiotis Balermpas, Jens von der Grün, Anca-Ligia Grosu, Jürgen Debus, Ute Ganswindt, Claus Belka, Jan C. Peeken, Stephanie E. Combs, Chiara De-Colle, Daniel Zips, Gustavo B. Baretton, Mechthild Krause, and Michael Baumann

Subjects
Oncology, Validation, Medizin, Radiology, Nuclear Medicine and imaging, Hematology, Primary radiochemotherapy, Signature, HNSCC, Biomarkers
Abstract

Purpose: To develop prognostic biomarker signatures for patients with locally advanced head and neck squamous cell carcinoma (HNSCC) treated by primary radiochemotherapy (RCTx) based on previously published molecular analyses of the retrospective biomarker study of the German Cancer Consortium – Radiation Oncology Group (DKTK-ROG).

Published
2022
Full Text
View/download PDF

3. Irradiation of regional lymph node areas in breast cancer – Dose evaluation according to the Z0011, AMAROS, EORTC 10981-22023 and MA-20 field design

Author

Gabriel Buschner, Stephanie E. Combs, Kai Joachim Borm, Markus Oechsner, M.N. Duma, Mathias Düsberg, and Wolfgang A. Weber

Subjects
Adult, medicine.medical_treatment, Breast Neoplasms, 030218 nuclear medicine & medical imaging, law.invention, 03 medical and health sciences, 0302 clinical medicine, Breast cancer, Randomized controlled trial, Fluorodeoxyglucose F18, law, Treatment plan, Positron Emission Tomography Computed Tomography, medicine, Humans, Radiology, Nuclear Medicine and imaging, Radiation treatment planning, Lymph node, Neoplasm Staging, Randomized Controlled Trials as Topic, business.industry, Radiotherapy Planning, Computer-Assisted, Hematology, Middle Aged, medicine.disease, Radiation therapy, medicine.anatomical_structure, Lymphatic system, Oncology, Lymphatic Metastasis, Positron-Emission Tomography, 030220 oncology & carcinogenesis, Axilla, Female, Lymph Nodes, Level ii, Nuclear medicine, business
Abstract

Objective The purpose of this study was to estimate the dose distribution from randomized trials (MA.20, EORTC 22922-10925 (EORTC), AMAROS and the Z0011 trial) on lymph node (LN) irradiation on a large LN atlas. Methods 580 F18-FDG-PET/CT positive LN metastases of 235 patients were transferred rigidly and non-rigidly to three “template CTs” (standard, obese and slender patient). Further, the LN clinical target volumes (CTVs) were contoured according to the ESTRO-guidelines. Treatment plans were designed (each for the left and right side) for all patients based on the study protocols of the MA.20, EORTC, AMAROS and Z0011 trial. Subsequently, the dose distribution in the ESTRO-CTVs and in the 580 LNs were assessed. Results Our results reveal variable dose coverage (26.8 ± 17.3 Gy–53.0 ± 1.8 Gy) in the targeted LN areas (ESTRO-CTV and LN) in dependence of the treatment planning design and the patients’ body shape. None of the treatment plan designs provided full dose coverage to the lymphatic drainage system. High tangent irradiation resulted in a similar dose distribution in L I and II compared to the AMAROS field design. Conclusion Inclusion of the entire lymphatic system may not be necessary for all patients to reproduce the oncologic benefit shown in the randomized LN-irradiation trials. Inclusion of axillary level II and extension of the supraclavicular CTV can be considered in selected high-risk patients, based on dose recalculation of the MA.20 trial. Further, our results amplify earlier assumptions that irradiation may have accounted for the good results after SLND alone in the Z0011 trial.

Published
2020
Full Text
View/download PDF

4. OC-0638 Integrated radiogenomics analyses for outcome prognosis in patients with locally advanced HNSCC

Author

Goda Kalinauskaite, M. Krause, Daniel Zips, Claus Belka, Maja Guberina, Michael H. Baumann, J.C. Peecken, J. von der Grün, Fabian Lohaus, Esther G.C. Troost, A. Rabasco, Annett Linge, Panagiotis Balermpas, Alex Zwanenburg, Inge Tinhofer, S. Böcke, U. Ganswindt, Gustavo B. Baretton, Steffen Löck, Stephanie E. Combs, M. Grosser, and Nika Guberina

Subjects
Oncology, medicine.medical_specialty, business.industry, Internal medicine, Radiogenomics, medicine, Locally advanced, Radiology, Nuclear Medicine and imaging, In patient, Hematology, business, Outcome (game theory)
Published
2021
Full Text
View/download PDF

5. PD-0933 Microbeam radiotherapy planning for a clinical lung tumor case

Author

Stefan Bartzsch, Jan J. Wilkens, J. Winter, Mahmoud Ahmed, K. M. Kraus, and Stephanie E. Combs

Subjects
Radiation therapy, medicine.medical_specialty, Oncology, business.industry, medicine.medical_treatment, Medicine, Radiology, Nuclear Medicine and imaging, Lung tumor, Hematology, Microbeam, Radiology, business
Published
2021
Full Text
View/download PDF

6. OC-0277 A 6-gene signature for loco-regional control prognosis in HNSCC patients treated by PORT-C

Author

Claus Belka, Michael H. Baumann, Jürgen Debus, David Mönnich, Volker Budach, Amir Abdollahi, Claus Rödel, Ali Sak, Inge Tinhofer, Annett Linge, S. Patil, Daniel Zips, Gustavo B. Baretton, Henning Schäfer, Steffen Löck, Steffi Pigorsch, U. Ganswindt, Panagiotis Balermpas, Volker Gudziol, A. Nowak, M. Stuschke, M. Grosser, M. Krause, Stephanie E. Combs, and A.L. Grosu

Subjects
Oncology, medicine.medical_specialty, business.industry, Internal medicine, Medicine, Radiology, Nuclear Medicine and imaging, Hematology, Gene signature, business, Port (computer networking)
Published
2021
Full Text
View/download PDF

7. OC-0626 Toxicity of SRT combined with targeted agents: prospective analysis of the TOaSTT database

Author

Franziska Eckert, F. Koppe, V. Lewitzki, A. Wittig-Sauerwein, Ilinca Popp, H. Geinitz, K. Baumann, F.L. Schneiders, Oliver Blanck, S. Rogers, Stephanie E. Combs, Fabian Lohaus, S. Benavente, G. Skazikis, David Kaul, Stephanie G. C. Kroeze, Joost J.C. Verhoeff, Susanne Stera, K.H. Kahl, J. Schaule, M. Spaas, Shankar Siva, K. De Jaeger, Markus M. Schymalla, and M. Guckenberger

Subjects
Oncology, Prospective analysis, medicine.medical_specialty, business.industry, Internal medicine, Toxicity, medicine, Radiology, Nuclear Medicine and imaging, Hematology, business
Published
2021
Full Text
View/download PDF

9. SDF-1/CXCR4 expression is an independent negative prognostic biomarker in patients with head and neck cancer after primary radiochemotherapy

Author

Jehad Abu Jawad, Amir Abdollahi, Mechthild Krause, Inge Tinhofer, Daniel Zips, Martin Stuschke, Volker Budach, Steffi Pigorsch, Bence Sipos, Panagiotis Balermpas, Annett Linge, Michael Baumann, Stefan Welz, David Mönnich, Claus Belka, Jürgen Debus, S. Boeke, Anca-Ligia Grosu, Dktk-Rog, Paul-Stefan Mauz, Chiara De-Colle, Ute Ganswindt, Stephanie E. Combs, Apostolos Menegakis, Claus Rödel, Falko Fend, and Fabian Lohaus

Subjects
Male, 0301 basic medicine, Oncology, Chemokine, Multivariate analysis, Cell, Medizin, CXCR4, 0302 clinical medicine, Prospective Studies, Head and neck cancer, medicine.diagnostic_test, biology, Hazard ratio, Chemoradiotherapy, Hematology, Middle Aged, Prognosis, Survival Rate, medicine.anatomical_structure, Head and Neck Neoplasms, 030220 oncology & carcinogenesis, Carcinoma, Squamous Cell, Biomarker (medicine), Female, Receptors, CXCR4, medicine.medical_specialty, Primary radiochemotherapy, Prognostic, Immunofluorescence, SDF-1, 03 medical and health sciences, Internal medicine, Biomarkers, Tumor, medicine, Humans, Radiology, Nuclear Medicine and imaging, Aged, Neoplasm Staging, Retrospective Studies, Squamous Cell Carcinoma of Head and Neck, business.industry, Biomarker, medicine.disease, Chemokine CXCL12, 030104 developmental biology, biology.protein, Neoplasm Recurrence, Local, business
Abstract

Introduction Preclinical and clinical data suggest that the chemokine pathway governed by SDF-1 and CXCR4 contributes to a resistant phenotype. This retrospective biomarker study aims to explore the specific prognostic value of SDF-1 and CXCR4 expression in locally advanced head and neck squamous cell carcinomas (HNSCC) treated with primary radiochemotherapy (RT-CT). Material and methods Biopsies from 141 HNSCC tumours of the oral cavity, oropharynx and hypopharynx were evaluated for SDF-1 and CXCR4 expression by immunofluorescence. SDF-1 and CXCR4 expression was correlated with clinico-pathological characteristics and outcome after RT-CT. Results Patients with tumours exhibiting overexpression of intracellular SDF-1 and CXCR4 have a higher risk for loco-regional relapse and a worse overall survival after RT-CT (multivariate analysis, hazard ratio 2.33, CI [1.18–4.62], p = 0.02 and hazard ratio 2.02, CI [1.13–3.59], p = 0.02, respectively). Similar results were observed when only the subgroup of HPV DNA negative patients were analysed (hazard ratio 2.23 and 2.16, p = 0.02 and p = 0.01, respectively). Conclusions Our data support the importance of SDF-1 and CXCR4 expression for loco-regional control and overall survival in HNSCC after primary radiochemotherapy. Prospective multivariate validation and further studies into CXCR4 inhibition to overcome radiation resistance are warranted.

Published
2018
Full Text
View/download PDF

13. PO-1540: Radiomic models for validation in patients with locally advanced HNSCC treated with primary RTCx

Author

Martin Stuschke, Christian Richter, K. Pilz, V. Budauch, Daniel Zips, Steffi Pigorsch, Alex Zwanenburg, A. Rabasco, Stefan Leger, Panagiotis Balermpas, Ute Ganswindt, Fabian Lohaus, Claus Belka, Joerg Kotzerke, David Mönnich, Claus Rödel, K. Zöphel, Andreas Schreiber, Stephanie E. Combs, Michael H. Baumann, Annett Linge, Esther G.C. Troost, Inge Tinhofer, M. Krause, and Steffen Löck

Subjects
Oncology, medicine.medical_specialty, Primary (chemistry), business.industry, Internal medicine, medicine, Locally advanced, Radiology, Nuclear Medicine and imaging, In patient, Hematology, business
Published
2020
Full Text
View/download PDF

14. PD-0066: A 24-miRNA signature predicting HPV status in head and neck cancer

Author

Daniel Zips, P. Weber, Claus Rödel, Michael Henke, Martin Werner, M. Krause, Annett Linge, Jürgen Debus, Lars Schüttrumpf, Stephanie E. Combs, Philipp Baumeister, Kristian Unger, J. Heß, Henning Schäfer, Cornelius Maihoefer, H. Zitzelsberger, T. Heider, Axel Walch, U. Ganswindt, B. Michael, Martin Stuschke, C. Woischke, S. Marschner, Claus Belka, and Inge Tinhofer

Subjects
Oncology, Mirna signature, medicine.medical_specialty, business.industry, Internal medicine, Head and neck cancer, medicine, Radiology, Nuclear Medicine and imaging, Hematology, medicine.disease, business, Hpv status
Published
2020
Full Text
View/download PDF

16. OC-0570: Validating gene signatures in locally advanced HNSCC patients treated by PORT-C and in xenografts

Author

Claus Rödel, Stephanie E. Combs, Annett Linge, Panagiotis Balermpas, Jürgen Debus, M. Krause, Bouchra Tawk, David Mönnich, Gustavo B. Baretton, Henning Schäfer, Fabian Lohaus, Volker Gudziol, Kristin Gurtner, Volker Budach, Claus Belka, M. Stuschke, Michael H. Baumann, Amir Abdollahi, Inge Tinhofer, A.L. Grosu, M. Großer, A. Nowak, S. Patil, Daniel Zips, and Steffen Löck

Subjects
Port (medical), Oncology, business.industry, Medizin, Locally advanced, Cancer research, Medicine, Radiology, Nuclear Medicine and imaging, Hematology, business
Published
2020
Full Text
View/download PDF

21. Comparative analysis of the effects of radiotherapy versus radiotherapy after adjuvant chemotherapy on the composition of lymphocyte subpopulations in breast cancer patients

Author

Eva K. Sage, Michael Sedelmayr, Gabriele Multhoff, Mathias Gehrmann, Thomas Schmid, Hans Geinitz, Stephanie E. Combs, and Marciana Nona Duma

Subjects
Adult, 0301 basic medicine, Oncology, medicine.medical_specialty, Lymphocyte, medicine.medical_treatment, Breast Neoplasms, 03 medical and health sciences, 0302 clinical medicine, Breast cancer, T-Lymphocyte Subsets, Internal medicine, medicine, Humans, Radiology, Nuclear Medicine and imaging, Aged, Chemotherapy, business.industry, FOXP3, Cancer, Chemoradiotherapy, Hematology, Middle Aged, medicine.disease, Radiation therapy, 030104 developmental biology, medicine.anatomical_structure, Chemotherapy, Adjuvant, 030220 oncology & carcinogenesis, Immunology, Female, business, Adjuvant
Abstract

Background Breast cancer is the most common cancer in women worldwide and surgery, radiotherapy (RT) and chemotherapy (ChT) are frequently used to treat this cancer. Adjuvant RT has been shown to cause long-term changes in lymphocyte counts in the peripheral blood. Herein, the time course of changes in lymphocyte subpopulations upon RT was studied in patients with and without adjuvant ChT in order to explore its potential clinical impact. Materials and methods Total lymphocyte counts and the composition of lymphocyte subpopulations before RT (t0), after 30Gy (t1), at the end of RT (t2), and 6weeks (t3), 6months (t4), and 1year (t5) after RT were studied by flow cytometry. Results Absolute lymphocyte counts were significantly lower in all breast cancer patients ( n =40) before and also 1year after RT compared to healthy controls. The percentage of CD3 + /CD4 + helper T cells and FoxP3 + regulatory T cells increased significantly in patients without adjuvant ChT. Different NK cell subpopulations dropped during RT in patients with and without ChT, but recovered to initial levels 6months after RT (t4). During RT (t0–t2) the percentage of CD19 + B cells significantly dropped in patients without ChT, but gradually increased in patients with adjuvant ChT. Both patient groups reached initial levels 6months after RT (t4). Conclusion Different lymphocyte subpopulations respond differently to RT with and without adjuvant ChT. CD4 + T cells increase during RT, whereas NK cells and B cells decrease in patients without ChT, but recover within 6months after RT. Treg cells gradually increase in patients without ChT from t0 to t5, but not in patients with adjuvant ChT.

Published
2016
Full Text
View/download PDF

22. SP-0518: Development and validation of a deltaradiomics response model for neoadjuvant radiotherapy of soft tissue sarcomas

Author

Matthew J. Nyflot, Katja Specht, Stephanie E. Combs, Daniel S Hippe, Edward Y. Kim, Nina A. Mayr, Eleanor Y. Chen, and Jan C. Peeken

Subjects
Radiation therapy, medicine.medical_specialty, Oncology, Response model, business.industry, medicine.medical_treatment, medicine, Soft tissue, Radiology, Nuclear Medicine and imaging, Hematology, Radiology, business
Published
2020
Full Text
View/download PDF

23. PH-0600: Distribution patterns of lymphatic metastases: influence of axillary lymph node dissection

Author

Mathias Düsberg, Kai Joachim Borm, M.N. Duma, Stephanie E. Combs, C.A.M. Schleibinger, J. Voppichler, and Markus Oechsner

Subjects
Pathology, medicine.medical_specialty, Lymphatic system, Oncology, business.industry, Axillary Lymph Node Dissection, Medicine, Distribution (pharmacology), Radiology, Nuclear Medicine and imaging, Hematology, business
Published
2020
Full Text
View/download PDF

25. PO-1169: Influence of localisation of PSMA-positive oligo-metastases on efficacy of metastasis-directed EBRT

Author

Peter Bartenstein, Thorsten Derlin, Hans Christiansen, C. Lafougere, M. Guckenberger, A. Müller, Marco M. E. Vogel, Matthias Eiber, J. Becker, Michael Mix, Nina-Sophie Schmidt-Hegemann, Claus Belka, Simon Kirste, S.G.C. Kroeze, A.L. Grosu, Irene A. Burger, Stephanie E. Combs, and C. Henkenberens

Subjects
Oncology, business.industry, Cancer research, medicine, Radiology, Nuclear Medicine and imaging, Hematology, medicine.disease, business, Metastasis
Published
2020
Full Text
View/download PDF

26. OC-0453: Efficacy and safety of stereotactic radiotherapy combined with TKIs for metastatic lesions

Author

Fabian Lohaus, Stephanie E. Combs, Shankar Siva, Oliver Blanck, M. Szuecs, An Claes, G. Henke, A. Nateghian, M. Guckenberger, Sonja Adebahr, M. Geier, David Kaul, C. Fritz, Daniel Buergy, K.H. Kahl, Markus M. Schymalla, S. Gerum, S.G.C. Kroeze, Nora Sundahl, and A. Wittig

Subjects
Stereotactic radiotherapy, medicine.medical_specialty, Metastatic lesions, Oncology, business.industry, Medicine, Radiology, Nuclear Medicine and imaging, Hematology, Radiology, business
Published
2020
Full Text
View/download PDF

27. PO-1632: Planning target volume (PTV) reduction for gated stereotactic body radiotherapy(SBRT) of lung tumors

Author

Stephanie E. Combs, Markus Oechsner, K. M. Kraus, and Jan J. Wilkens

Subjects
Lung, medicine.anatomical_structure, Oncology, business.industry, medicine.medical_treatment, Planning target volume, Medicine, Radiology, Nuclear Medicine and imaging, Hematology, business, Nuclear medicine, Stereotactic body radiotherapy, Reduction (orthopedic surgery)
Published
2020
Full Text
View/download PDF

30. OC-0386 A PET-based patterns of failure analysis in the context of contouring guidelines in anal cancer

Author

Stephanie E. Combs, Hendrik Dapper, Wolfgang Weber, Stefan Münch, Jan C. Peeken, Kilian Schiller, and Kai Joachim Borm

Subjects
Patterns of failure, Contouring, medicine.medical_specialty, Oncology, business.industry, medicine, Anal cancer, Radiology, Nuclear Medicine and imaging, Context (language use), Hematology, Radiology, medicine.disease, business
Published
2019
Full Text
View/download PDF

34. OC-0166 Cumulative metastases volume, not number of brain metastases predicts survival in melanoma patients

Author

M. Guckenberger, G. Henke, Franziska Eckert, Susanne Stera, Fabian Lohaus, S. Gerum, Nora Sundahl, Daniel Buergy, A. Haap, An Claes, K.H. Kahl, Stephanie E. Combs, Oliver Blanck, M. Szuecs, S.G.C. Kroeze, N. Abbasi-Senger, Markus M. Schymalla, A.L. Grosu, J. Heitmann, and M. Geier

Subjects
medicine.medical_specialty, Oncology, Volume (thermodynamics), business.industry, Melanoma, medicine, Radiology, Nuclear Medicine and imaging, Hematology, Radiology, medicine.disease, business
Published
2019
Full Text
View/download PDF

35. EP-1465 Impact of diabetes on outcome and toxicity of neoadjuvant (chemo) radiation for rectal cancer

Author

Stephanie E. Combs, K. Stemmer, S. Muench, D. Bierbaumer, P.T. Pfluger, B. Haller, and Daniel Habermehl

Subjects
Oncology, medicine.medical_specialty, Colorectal cancer, business.industry, Hematology, medicine.disease, Chemo radiation, Diabetes mellitus, Internal medicine, Toxicity, medicine, Radiology, Nuclear Medicine and imaging, business
Published
2019
Full Text
View/download PDF

36. OC-0496 Deep-learning based estimation of locoregional control for patients with locally advanced HNSCC

Author

Fabian Lohaus, Alex Zwanenburg, Claus Belka, Martin Stuschke, Andreas Schreiber, Inge Tinhofer, M. Krause, Steffi Pigorsch, Stefan Leger, Panagiotis Balermpas, Christian Richter, K. Pilz, Michael H. Baumann, Ute Ganswindt, Sebastian Starke, Joerg Kotzerke, K. Zöphel, Esther G.C. Troost, David Mönnich, Volker Budach, Stephanie E. Combs, Claus Rödel, Annett Linge, Steffen Löck, and Daniel Zips

Subjects
Estimation, Oncology, business.industry, Computer science, Deep learning, Locally advanced, Radiology, Nuclear Medicine and imaging, Hematology, Artificial intelligence, business, Machine learning, computer.software_genre, computer
Published
2019
Full Text
View/download PDF

37. EP-1256 Influence of PET-imaging during treatment planning on outcome in meningioma patients

Author

Kerstin A. Kessel, Christian Diehl, Wolfgang A. Weber, Stephanie E. Combs, T. Voglhuber, H. Fischer, and Christoph Straube

Subjects
Meningioma, medicine.medical_specialty, Oncology, business.industry, medicine, Radiology, Nuclear Medicine and imaging, Hematology, Pet imaging, Radiology, medicine.disease, Radiation treatment planning, business, Outcome (game theory)
Published
2019
Full Text
View/download PDF

39. OC-0163 Risk classification for PSA relapse after PSMAPET-guided RT for oligorecurrent prostate cancer

Author

Nina-Sophie Schmidt-Hegemann, Stephanie E. Combs, A. Müller, Hans Christiansen, S.G.C. Kroeze, J. Becker, Claus Belka, M. Guckenberger, C. Henkenberens, A.L. Grosu, Marco M. E. Vogel, and Simon Kirste

Subjects
Oncology, medicine.medical_specialty, Prostate cancer, business.industry, Internal medicine, Medicine, Radiology, Nuclear Medicine and imaging, Hematology, business, medicine.disease, Risk classification, Psa relapse
Published
2019
Full Text
View/download PDF

40. EP-1522 Radiotherapy with or without antihormonal therapy for PSMA-positive oligorecurrent prostate cancer

Author

Hans Christiansen, J. Becker, M. Guckenberger, Claus Belka, A. Müller, A.L. Grosu, Marco M. E. Vogel, S. Kroeze, Nina-Sophie Schmidt-Hegemann, Stephanie E. Combs, C. Henkenberens, and Simon Kirste

Subjects
Oncology, Radiation therapy, medicine.medical_specialty, Prostate cancer, business.industry, Internal medicine, medicine.medical_treatment, medicine, Radiology, Nuclear Medicine and imaging, Hematology, medicine.disease, business
Published
2019
Full Text
View/download PDF

43. Long-term outcome after highly advanced single-dose or fractionated radiotherapy in patients with vestibular schwannomas – Pooled results from 3 large German centers

Author

Anca-Ligia Grosu, Nicole Wiedenmann, Jürgen Debus, Stephanie E. Combs, Oliver Schramm, Christine Kopp, Michael Molls, Christina Engelhard, and V. Prokic

Subjects
Adult, Male, medicine.medical_specialty, Adolescent, Fractionated radiotherapy, medicine.medical_treatment, Acoustic neuroma, Radiosurgery, Young Adult, Hearing, parasitic diseases, medicine, Humans, Radiology, Nuclear Medicine and imaging, In patient, Aged, Aged, 80 and over, Hearing preservation, business.industry, Radiotherapy Planning, Computer-Assisted, Neuroma, Acoustic, Hematology, Middle Aged, medicine.disease, Facial nerve, Tumor Burden, Surgery, Radiation therapy, Facial Nerve, Treatment Outcome, Oncology, Vestibular Schwannomas, Female, Dose Fractionation, Radiation, Radiology, business, Follow-Up Studies
Abstract

Purpose To evaluate long-term clinical outcome and determine prognostic factors for local-control, hearing preservation and cranial nerve toxicity in 449 patients treated for 451 vestibular schwannomas (VS) with radiosurgery ( n =169; 38%) or fractionated stereotactic radiotherapy (FSRT; n =291; 62%). Methods and materials 245 patients were male (55%), and 204 were female (45%). Median age was 60years (range 17–88years). Median tumor diameter was 15mm. For FSRT, a median dose of 57.6Gy in median single doses of 1.8Gy was applied. For SRS, median dose was 13Gy. The median follow-up time was 67months. Results Local control was 97% at 36months, 95% at 60months, and 94% at 120months with no difference between FSRT and SRS ( p =0.39). " Useful hearing " was present 46%. After RT, " useful hearing " was preserved in 85% of the patients. Loss of useful hearing was observed in the FSRT group in 14%, and in the SRS group in 16% of the patients. For patients treated with SRS ⩽13Gy, useful hearing deterioration was 13%. For trigeminal and facial nerve toxicity, there was no difference between FSRT and SRS. Conclusion Supported by this large multicentric series, both SRS and FSRT can be recommended for the treatment of VS. SRS application is limited by tumor size, and is associated with a steep dose–response-curve. When chosen diligently based on tumor volume, pre-treatment characteristics and volume-dependent dose-prescription in SRS (⩽13Gy), both treatments may be considered equally effective.

Published
2015
Full Text
View/download PDF

44. HPV16 DNA status is a strong prognosticator of loco-regional control after postoperative radiochemotherapy of locally advanced oropharyngeal carcinoma: Results from a multicentre explorative study of the German Cancer Consortium Radiation Oncology Group (DKTK-ROG)

Author

Jürgen Debus, Amir Abdollahi, Fabian Lohaus, Melanie Avlar, Anca-Ligia Grosu, Annett Linge, Claus Rödel, Eleni Gkika, Steffen Löck, Daniel Zips, Christine Bayer, Mechthild Krause, Howard D. Thames, Gustavo B. Baretton, Michael Baumann, Volker Budach, David Mönnich, Cläre von Neubeck, Inge Tinhofer, Martin Stuschke, Steffi Pigorsch, Claus Belka, Panagiotis Balermpas, and Stephanie E. Combs

Subjects
Oncology, Male, p53, medicine.medical_specialty, HPV, Multivariate analysis, Locally advanced, Medizin, p16, HNSCC, Internal medicine, medicine, Clinical endpoint, Humans, Radiology, Nuclear Medicine and imaging, Postoperative Period, Prospective Studies, ddc:610, Papillomaviridae, Cyclin-Dependent Kinase Inhibitor p16, Retrospective Studies, Cisplatin, Univariate analysis, business.industry, Squamous Cell Carcinoma of Head and Neck, DKTK-ROG, Cancer, Chemoradiotherapy, DNA, Hematology, medicine.disease, Prognosis, Head and neck squamous-cell carcinoma, Survival Analysis, Oropharyngeal Neoplasms, Treatment Outcome, Oropharyngeal Carcinoma, Postoperative radiochemotherapy, Head and Neck Neoplasms, Radiology Nuclear Medicine and imaging, Carcinoma, Squamous Cell, Female, business, medicine.drug
Abstract

Objective: To investigate the impact of HPV status in patients with locally advanced head and neck squamous cell carcinoma (HNSCC), who received surgery and cisplatin-based postoperative radiochemotherapy. Materials and methods: For 221 patients with locally advanced squamous cell carcinoma of the hypopharynx, oropharynx or oral cavity treated at the 8 partner sites of the German Cancer Consortium, the impact of HPV DNA, p16 overexpression and p53 expression on outcome were retrospectively analysed. The primary endpoint was loco-regional tumour control; secondary endpoints were distant metastases and overall survival. Results: In the total patient population, univariate analyses revealed a significant impact of HPV16 DNA positivity, p16 overexpression, p53 positivity and tumour site on loco-regional tumour control. Multivariate analysis stratified for tumour site showed that positive HPV 16 DNA status correlated with loco-regional tumour control in patients with oropharyngeal carcinoma (p = 0.02) but not in the oral cavity carcinoma group. Multivariate evaluation of the secondary endpoints in the total population revealed a significant association of HPV16 DNA positivity with overall survival (p

Published
2014
Full Text
View/download PDF

45. EP-1216: Variation of the blood glucose during radiotherapy: an analysis among glioblastoma patients

Author

Markus Oechsner, T. Boeckh-Behrens, N.I. Oszfolk, Kai Joachim Borm, M.N. Duma, Stephanie E. Combs, and Michael Mayinger

Subjects
Oncology, medicine.medical_specialty, business.industry, medicine.medical_treatment, Hematology, medicine.disease, Radiation therapy, Variation (linguistics), Internal medicine, Medicine, Radiology, Nuclear Medicine and imaging, business, Glioblastoma
Published
2018
Full Text
View/download PDF

48. EP-2323: Effects of the proteasome inhibitor bortezomib on radiosensitivity of glioblastoma cells

Author

C. Forster, Thomas Schmid, Daniela Schilling, M. Wank, and Stephanie E. Combs

Subjects
0301 basic medicine, Bortezomib, business.industry, Hematology, medicine.disease, 03 medical and health sciences, 030104 developmental biology, 0302 clinical medicine, Oncology, 030220 oncology & carcinogenesis, Cancer research, medicine, Proteasome inhibitor, Radiology, Nuclear Medicine and imaging, Radiosensitivity, business, Glioblastoma, medicine.drug
Published
2018
Full Text
View/download PDF

49. EP-1324: Hypo- vs Normofractionated RT in Early Breast Cancer – Patterns of Care in German speaking countries

Author

M.N. Duma, Daniel Habermehl, Michael Mayinger, Kai Joachim Borm, Christoph Straube, and Stephanie E. Combs

Subjects
Oncology, Patterns of care, medicine.medical_specialty, business.industry, Hematology, language.human_language, German, Internal medicine, language, Medicine, Radiology, Nuclear Medicine and imaging, business, Early breast cancer
Published
2018
Full Text
View/download PDF

50. EP-1389: Reduction of lung dose during stereotactic radiation of lung tumors using respiratory gating

Author

Stephanie E. Combs, M.N. Duma, Jan J. Wilkens, M. Wiegandt, A. Hofmeister, and Markus Oechsner

Subjects
Lung, medicine.anatomical_structure, Oncology, Stereotactic radiation, business.industry, medicine.medical_treatment, Respiratory gating, Medicine, Radiology, Nuclear Medicine and imaging, Hematology, business, Nuclear medicine, Reduction (orthopedic surgery)
Published
2018
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results